EIF3J

Across TCGA pan-cancer cohorts, EIF3J Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated EIF3J data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher EIF3J Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated EIF3J expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SKCM, COAD, and BLCA are the cancer types where EIF3J Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	All	0.232	0.787	.002	27	view →
COAD	OS	Median	II,III,IV	0.001	0.860	<.001	12	view →
BLCA	DFS	Median	All	0.139	0.626	.010	9	view →
UCEC	OS	Median	II,III,IV	0.933	0.507	.038	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

EIF3J–SKCM (OS)

Open the SKCM breakdown →